South Africa's Afrigen Biologics uses the publicly available sequence of the mRNA-based Moderna COVID-19 vaccine to make its own version of the vaccine, which will become the world's first vaccine based on an existing vaccine once it is tested on humans later this year.
South Africa's Afrigen Biologics uses the publicly available sequence of mRNA-based Moderna COVID-19 vaccine to make its own version of the shot, which is slated to become the world's first vaccine to made based on a widely-existing vaccine once it is tested on humans by the end of the year.
South Africa's Afrigen Biologics uses the publicly available sequence of themRNA-based Moderna COVID-19 vaccine to make its own version of the vaccine, which will become the world's first vaccine based on an existing vaccine once it is tested on humans later this year.